BiBBInstruments rights issue

BiBBInstruments

Subscription price: 0.37 SEK per share
Brokerage fee: No brokerage fee
Issuance amount: Approximately 60 million SEK
Subscription period: March 30 - April 13 2026
Trading in share rights: March 30 - April 8 2026
Marketplace: Spotlight Stock Market
Company website: https://bibbinstruments.com/en/

About BiBBInstruments

BiBBInstruments AB is a cancer diagnostics company that develops and commercializes EndoDrill®, the world's first series of powered endoscopic biopsy instruments with market clearance in the United States and CE marking in Europe. EndoDrill® is designed to collect core tissue samples (core needle biopsies, CNB) with high diagnostic accuracy and aims to improve the diagnosis of cancer in, among others, the stomach, pancreas, liver, lungs and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments in modern endoscopy. 

BiBB received market clearance (510(k)) from the U.S. Food and Drug Administration (FDA) for its first instrument, EndoDrill® GI, in 2023 and obtained CE marking under the EU Medical Device Regulation (MDR) in 2024 for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. The U.S. launch of EndoDrill® GI was initiated in the autumn of 2025 in collaboration with TaeWoong Medical USA. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. 

BiBB was founded in 2013 by Dr Charles Walther, a cancer researcher at Lund University and a senior consultant in clinical pathology at Skåne University Hospital. The company is headquartered at Medicon Village in Lund, Sweden, and its shares are traded on Spotlight Stock Market (ticker: BIBB).